Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
暂无分享,去创建一个
Jeffrey A Jones | J. Byrd | F. Awan | A. Johnson | T. Diacovo | S. O'brien | A. Schuh | J. Pagel | Jennifer R. Brown | Xiaolin Wang | W. Wierda | A. Hamdy | R. Furman | P. Ghia | S. Devereux | P. Hillmen | J. Chaves | D. Stephens | R. Izumi | B. Harrington | J. Woyach | A. Kaptein | J. Barrientos | B. Lannutti | M. Fardis | J. McGreivy | D. Johnson | Wayne P. Rothbaum | T. Covey | Jane Huang | Wayne Rothbaum | J. Mcgreivy | Bonnie K. Harrington
[1] T. Miller,et al. Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia , 2016, Haematologica.
[2] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[3] J. Murphy,et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants , 2015, Pharmacology research & perspectives.
[4] Jeffrey A Jones,et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.
[5] Susan O'Brien,et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. , 2015, Blood.
[6] J. Byrd,et al. Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma , 2014 .
[7] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[8] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.
[9] R. Ulrich,et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.
[10] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[11] Lisa L. Smith,et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). , 2014, Blood.
[12] Jeffrey A Jones,et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.
[13] T. Miller,et al. Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) , 2013 .
[14] Jeffrey A Jones,et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.
[15] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[16] Juswinder Singh,et al. Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[17] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[18] A. Langerak,et al. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. , 2013, American journal of blood research.
[19] J. Neffendorf,et al. Ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[20] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[21] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[22] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[23] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[24] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[25] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[26] M. Keating,et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. , 2009, Blood.
[27] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[28] R. Liddington,et al. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies , 2008, Nature Biotechnology.
[29] Edward S. Kim,et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. , 2007, The oncologist.
[30] S. Watson,et al. Tec regulates platelet activation by GPVI in the absence of Btk. , 2003, Blood.
[31] H. Mano,et al. Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets , 1998, Oncogene.
[32] H. Ochs,et al. Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families. , 1994, Human Molecular Genetics.
[33] O. Witte,et al. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. , 1994, The New England journal of medicine.
[34] D J Rawlings,et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.
[35] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .